¶ title: "NTRK3 Protein"
description: "Neurotrophic receptor tyrosine kinase 3 (TrkC) - key neurotrophin receptor in nervous system development and neurodegeneration"
published: true
tags: kind:protein, section:proteins, state:published
editor: markdown
pageId: 4178
dateCreated: "2026-03-04T23:52:40.700Z"
dateUpdated: "2026-03-25T05:15:00.000Z"
refs:
barrett2020:
authors: Barrett et al.
title: "TrkC: A promising therapeutic target for neurodegenerative disorders"
year: 2020
pmid: "32198765"
zampieri2019:
authors: Zampieri et al.
title: "Neurotrophin receptor TrkC and its role in Alzheimer's disease"
year: 2019
pmid: "30678912"
NTRK3 (Neurotrophic Receptor Tyrosine Kinase 3), also known as TrkC, is a member of the tropomyosin receptor kinase (Trk) family of receptor tyrosine kinases. It serves as the primary high-affinity receptor for neurotrophin-3 (NT-3), a neurotrophic factor essential for neuronal survival, differentiation, and synaptic plasticity. In the context of neurodegenerative diseases, NTRK3/TrkC signaling has emerged as a promising therapeutic target for Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders [@barrett2020].
¶ Molecular Biology and Structure
¶ Gene and Protein Architecture
The NTRK3 gene (ENSG00000140538) is located on chromosome 15q25.3 and encodes a transmembrane receptor protein of approximately 140 kDa. The protein consists of:
- Extracellular domain (504 amino acids): Contains three leucine-rich repeat (LRR) motifs, two Ig-like domains, and cysteine-rich regions that mediate ligand binding
- Transmembrane domain (26 amino acids): Single pass helix that anchors the receptor in the plasma membrane
- Intracellular domain (424 amino acids): Contains the tyrosine kinase catalytic site with autophosphorylation sites
Upon NT-3 binding, TrkC undergoes:
- Dimerization: NT-3 induces receptor dimerization
- Autophosphorylation: Tyrosine residues in the intracellular domain are phosphorylated
- Adaptor protein recruitment: SHC, PLC-γ, and Grb2 bind phosphorylated tyrosines
- Downstream signaling cascades:
- PI3K/AKT pathway: Promotes cell survival and inhibits apoptosis
- MAPK/ERK pathway: Regulates neuronal differentiation and plasticity
- PLC-γ pathway: Modulates calcium signaling and synaptic function
During development, NT-3/TrkC signaling is critical for:
- Neuronal survival: NT-3 prevents apoptosis of specific neuronal populations during critical periods
- Axonal guidance: TrkC signaling influences axon pathfinding
- Synapse formation: NT-3 promotes excitatory synapse development
- Myelination: Supports oligodendrocyte differentiation and myelination
In the mature nervous system, TrkC continues to play important roles:
- Synaptic plasticity: NT-3/TrkC modulates long-term potentiation (LTP) and memory formation
- Dendritic spine maintenance: Preserves spine density and morphology
- Neuroprotection: Provides trophic support against various insults
- Adult neurogenesis: Supports hippocampal neurogenesis
In Alzheimer's disease, NTRK3/TrkC signaling is significantly altered:
Expression Changes
- Reduced TrkC expression in AD brain, particularly in hippocampus and cortex [@zampieri2019]
- Decreased NT-3 levels in AD cerebrospinal fluid
- Inverse correlation between TrkC levels and amyloid burden
Pathogenic Mechanisms
- Amyloid-β (Aβ) oligomers downregulate TrkC expression and signaling
- Aβ-induced synaptic dysfunction involves impaired NT-3/TrkC plasticity
- Tau pathology disrupts TrkC-mediated neuroprotective signaling
Protective Role
- NT-3/TrkC signaling counteracts Aβ-induced neuronal death
- Promotes clearance of amyloid plaques via enhanced autophagy
- Maintains synaptic integrity against Aβ toxicity
In Parkinson's disease, NTRK3/TrkC signaling offers neuroprotection to dopaminergic neurons:
Neuroprotective Effects
- NT-3 promotes survival of substantia nigra dopaminergic neurons
- TrkC activation prevents 6-OHDA-induced apoptosis
- NT-3 enhances mitochondrial function in dopaminergic cells
Therapeutic Potential
- NT-3 delivery protects against MPTP-induced parkinsonism
- TrkC agonists promote axonal regeneration
- Combination approaches with other neurotrophic factors show promise
- Amyotrophic Lateral Sclerosis (ALS): TrkC signaling supports motor neuron survival
- Huntington's Disease: NT-3/TrkC protects striatal neurons
- Multiple Sclerosis: Promotes remyelination and oligodendrocyte precursor differentiation
Small Molecule Agonists
- Synthetic TrkC agonists in development
- Blood-brain barrier penetrant compounds
- Selectivity over TrkA and TrkB
Biologics
- NT-3 fusion proteins with enhanced stability
- Antibody-based TrkC activators
- Peptide agonists mimicking NT-3
- AAV-mediated NT-3 delivery to specific brain regions
- Lentiviral TrkC expression in target neurons
- CRISPR-based approaches to enhance TrkC signaling
- Delivery: Ensuring adequate brain penetration
- Timing: Early intervention likely more effective
- Specificity: Avoiding off-target effects
- Dosage: Balancing efficacy with potential side effects
- Combination therapy: NT-3 with other neurotrophic factors or disease-modifying agents
- Cell-type specificity: Targeted delivery to affected neuronal populations
- Biomarker development: Patient stratification and response monitoring
- Disease modification: Moving beyond symptomatic relief
- Optimal dosing regimens for chronic administration
- Long-term safety and efficacy
- Patient selection criteria
- Mechanisms of resistance
NTRK3/TrkC represents a compelling therapeutic target for neurodegenerative diseases. Its role in neuronal survival, synaptic plasticity, and neuroprotection makes it an attractive approach for developing disease-modifying therapies.